2ND-LINE HORMONOTHERAPY FOR BREAST-CANCER - USELESSNESS OF 1ST-LINE CONTINUATION

被引：8

作者：

PRONZATO, P

RUBAGOTTI, A

AMOROSO, D

BERTELLI, G

QUEIROLO, P

SERTOLI, MR

ROSSO, M

GALLOTTI, P

MONZEGLIO, C

ROSSO, R

机构：

[1] GEN HOSP,VIGEVANO,ITALY

[2] ST ANNA HOSP,TURIN,ITALY

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1993年 / 16卷 / 06期

关键词：

HORMONOTHERAPY FOR BREAST CANCER; TAMOXIFEN; AMINOGLUTHETIMIDE;

D O I：

10.1097/00000421-199312000-00013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The hypothesis that the results of second line hormonotherapy for breast cancer may be ameliorated with continuation of the first line has been explored in a randomized trial. Patients progressing under tamoxifen were randomly allocated to aminoglutethimide and hydrocortisone acetate with or without tamoxifen continuation. No difference has been observed between the two arms in terms of response rate and progression-free or overall survival.

引用

页码：522 / 525

页数：4

共 9 条

[1] SENSITIVITY AND INSENSITIVITY OF BREAST-CANCER TO TAMOXIFEN [J].